hackint0sh/New-Dataset huggingface dataset:
Retinal cells are characterized by high oxygen consumption. Reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide and hydroxyl radical are the standard product of cellular metabolism within the mitochondria. Under physiological conditions, ROS are neutralized by a system of antioxidants. In case of cellular metabolism disturbances or insufficiency of the antioxidant system, an excess of ROS can be produced which contributes to oxidative stress, widely described as exerting deleterious effects on cells. The high oxygen requirement and low levels of antioxidant enzymes make the retina extremely sensitive to oxidative stress and more susceptible to cell death. Prevention of neuronal death in the retina becomes a crucial aspect for the management of WMD.
The treatment of choice for AMD today is the use of anti-VEGF (Vascular Endothelial Growth Factor) drugs, they are effective for neo-vascular AMD, acting on the inhibition of the angiogenic protein VEGF, which is produced in the retina and induced by hypoxia and other conditions. It is practice, however, to support the integration of nutritional supplements such as zinc, resveratrol, carotenoids such as lutein and zeaxanthin, vitamin E and Omega-3 fatty acids.
The aim of this study is to evaluate the efficacy of ozonated oil with high ozonides (HOO) administered orally as gastro-resistant capsules (O3Zone, GS Pharma, Malta), as an integrative and complementary treatment in patients affected by macular degeneration in the possible slowing of disease progression. conditions: Maculopathy studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: High ozonide (HOO) ozonated oil measure: evaluation of any slowing down of the maculopathy measure: evaluation of any slowing down of the maculopathy measure: evaluation of any slowing down of the maculopathy measure: evaluation of any slowing down of the maculopathy and closure of the study sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Neuromed city: Pozzilli country: Italy lat: 41.51142 lon: 14.06252 hasResults: False
nctId: NCT06351020 id: LM302-03-101 briefTitle: LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-08-10 date: 2026-12-15 date: 2024-04-08 date: 2024-04-08 name: LaNova Medicines Zhejiang Co., Ltd. class: INDUSTRY briefSummary: This study will assess the efficacy and safety of LM-302 Versus Treatment of Physician's Choice (TPC) in Subjects With locally advanced or metastatic, Claudin (CLDN) 18.2-positive, Gastric or Gastroesophageal Junction Adenocarcinoma who have progressed on or after 2 lines of systemic therapy conditions: Locally Advanced or Metastatic GC and GCJ Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: experimental arm:LM-302 control arm:Apatinib or Irinotecan primaryPurpose: TREATMENT masking: NONE count: 375 type: ESTIMATED name: LM-302 name: Apatinib name: Irinotecan measure: Overall Survival (OS) measure: Progression Free Survival (PFS) measure: Objective response rate (ORR) measure: Duration of response (DoR) measure: Disease control rate (DCR) measure: AE and SAE measure: Evaluate the immunogenicity of LM-302 measure: Evaluation of pharmacokinetic characteristics of LM-302 measure: Evaluation of pharmacokinetic characteristics of LM-302 measure: Evaluation of pharmacokinetic characteristics of LM-302 measure: Evaluation of pharmacokinetic characteristics of total antibody measure: Evaluation of pharmacokinetic characteristics of total antibody measure: Evaluation of pharmacokinetic characteristics of total antibody measure: Evaluation of pharmacokinetic characteristics of MMAE measure: Evaluation of pharmacokinetic characteristics of MMAE measure: Evaluation of pharmacokinetic characteristics of MMAE sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06351007 id: NMM-4650-23-24-1 briefTitle: Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK) acronym: EPAK overallStatus: RECRUITING date: 2023-09-19 date: 2024-07 date: 2024-07 date: 2024-04-08 date: 2024-04-08 name: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran class: OTHER briefSummary: A fundamental strategy to improve adherence to nutritional treatment in patients with chronic kidney disease is the implementation of educational programs. The aim of this study is to evaluate the effect of a multidisciplinary educational program on dietary adherence, nutritional knowledge, nutritional status, metabolic control and quality of life in patients with chronic kidney disease, predialysis, peritoneal dialysis and hemodialysis.
A randomized clinical trial will be carried out, in which patients who meet the inclusion criteria will be randomly assigned to three possible groups: predialysis educational intervention, dialysis educational intervention and control group. At the initial visit, the nutritional status will be evaluated by means of anthropometric parameters, screening and dynamometry, the biochemical parameters of interest will be extracted from the clinical record, nutritional knowledge and quality of life will be evaluated, and the diet will be explained. In the second visit, adherence to the diet will be evaluated and the food registry will be carried out. In the intervention groups, the educational program will begin with a duration of five months. Patients will come twice a month to the hospital to participate in the educational sessions and attend group psychology sessions. After completion of the educational program, the same measurements as at the beginning of the study will be carried out in the three groups. conditions: Chronic Kidney Disease conditions: Predialysis conditions: Peritoneal Dialysis conditions: Hemodialysis conditions: Educational Activities conditions: Adherence conditions: Nutritional Status studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 63 type: ESTIMATED name: Nutritional education and psychological intervention name: Standard care measure: Patients´ dietary attitude measure: Dietary adherence measure: Nutritional knowledge measure: Muscle status measure: Muscle functionality measure: Nutritional status of predialysis patients measure: Nutritional status of dialysis patients measure: Patients´ quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán status: RECRUITING city: Mexico City zip: 14080 country: Mexico name: Ximena Atilano Carsi, PhD role: CONTACT phone: 00 52 55 56 17 65 42 email: ximena.atilanoc@incmnsz.mx lat: 19.42847 lon: -99.12766 hasResults: False
nctId: NCT06350994 id: APHP230625 id: IDRCB 2023-A01957-38 type: OTHER domain: ANSM briefTitle: Early Assessment of Cardiac Function After Treatment With CAR-T Cells acronym: Cardio CAR-T overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-10 date: 2027-01 date: 2024-04-08 date: 2024-04-08 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: CAR-T cells (Chimeric Antigen Receptor) are a new immunotherapy, based on the genetic modification of autologous T lymphocytes. CAR-T cell therapy is not devoid of complications.
The main endpoint will be the change in cardiac function (LVEF: left ventricular ejection fraction) assessed by ultrasound between the pre CAR-T assessment and the early post CAR-T ultrasound (D3-D5). conditions: Car T- Cell conditions: Hematologic Malignancy conditions: Acute Lymphoblastic Leukemia conditions: Lymphoma, B-Cell conditions: Multiple Myeloma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED measure: Estimation of the incidence of possible early CAR-T cells infusion-induced cardiotoxicity measure: Characterization of the putative CAR-T cells infusion-induced cardiotoxicity: incidence, phenotype, clinical, rhythmic and biological manifestations measure: Determination of its possible association with a cytokine release syndrome and the levels of inflammatory biomarkers from the analysis of the serum library of these patients sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Critical care medicine department city: Paris zip: 75012 country: France name: Jérémie JOFFRE, MD, PhD role: CONTACT phone: +33 1 49 28 21 45 email: Jeremie.joffre@aphp.fr name: Hafid AIT-OUFELLA, Professor role: CONTACT phone: +33 1 49 28 21 45 email: hafid.ait-oufella@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06350981 id: FORE813 briefTitle: Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-01-01 date: 2025-03-01 date: 2024-04-08 date: 2024-04-08 name: Foundation for Orthopaedic Research and Education class: OTHER name: Pacira Pharmaceuticals, Inc briefSummary: The goal of this clinical trail is to to compare the efficacy of thoracolumbar interfascial plane block with Exparel vs with standard of care 0.25% Bupivacaine HCl in patients undergoing 1-3 level elective transforaminal lumbar interbody fusion. The investigators hypothesize that thoracolumbar interfascial plane block with Exparel will outperform standard of care (supplemented with interfascial plane block of 0.25% Bupivacaine HCl) with regards to pain reduction, narcotic use, length of hospital stay, time to mobilization with physical therapy, narcotic usage in the hospital, and post operative pain scores. conditions: Back Pain conditions: Surgery-Complications conditions: Narcotic Use conditions: Physical Stress conditions: Post Operative Pain studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Study subjects will be randomized to either Group 1 or Group 2 in a 1:1 ratio based on the randomization scheme in sealed envelopes maintained by the study coordinator. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 76 type: ESTIMATED name: Exparel name: Bupivacain measure: Compare efficacy of thoracolumbar interfacial plane block with Exparel vs. standard of care (0.25% Bupivacaine HCL) is surgical subjects undergoing 1-3 level elective transforaminal lumbar interbody fusion. measure: Total Postsurgical opioid consumption measure: Time to discharge measure: Time to ambulation measure: Maximum ambulated distance measure: Numeric Rating Pain Scale (Physical Therapy) measure: Numeric Rating Pain Scale measure: Oswestry Disability Index (ODI) measure: Pain Catastrophizing Scale (PCS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Foundation for Orthopaedic Research and Education city: Tampa state: Florida zip: 33607 country: United States name: Deborah H Warren role: CONTACT phone: 813-910-3688 email: dwarren@foreonline.org lat: 27.94752 lon: -82.45843 hasResults: False
nctId: NCT06350968 id: MEC-2023-0151 id: 10200012110003 type: OTHER_GRANT domain: ZonMw briefTitle: Implementation of Online Advance Care Planning Tool for (Hemato-)Oncological Patients Within the Cancer Network Concord acronym: INDEED overallStatus: RECRUITING date: 2023-10-01 date: 2026-06-30 date: 2026-12-31 date: 2024-04-08 date: 2024-04-08 name: Erasmus Medical Center class: OTHER name: Maasstad Hospital name: Spijkenisse Medical Center name: Franciscus &Vlietland name: IJsselland name: Ikazia Hospital, Rotterdam name: Van Weel-Bethesda hospital name: Albert Schweitzer Hospital name: Beatrix hospital briefSummary: The aim of this mixed-methods study is to describe both the implementation process and outcomes of the online module Advance Care Plan for (hemato-)oncology patients within the oncology-network CONCORD.
Healthcare providers and patients are asked to use the module and share their experiences with it. conditions: Oncology conditions: Advance Care Planning conditions: Implementation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED measure: Implementation outcome measure: Intervention outcome measure: Implementation outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Joica Benschop status: RECRUITING city: Rotterdam zip: 3023TB country: Netherlands name: Joica Benschop, MSc role: CONTACT phone: +31622586583 email: j.benschop@erasmusmc.nl name: Wendy Oldenmenger, PhD role: CONTACT phone: +31651072608 email: w.h.oldenmenger@erasmusmc.nl lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06350955 id: 2022-01389 briefTitle: IV Iron-induced Hypophosphatemia After RYGB acronym: IVORY overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-06 date: 2026-06 date: 2024-04-08 date: 2024-04-08 name: Lucie Favre class: OTHER briefSummary: The primary objective of the study is to compare the incidence of hypophosphatemia in RYGB patients treated with intravenous (IV) single dose of iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®). conditions: Hypophosphatemia conditions: Roux-en-Y Gastric Bypass studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 94 type: ESTIMATED name: Iron isomaltoside name: Iron Carboxymaltose measure: incidence of hypophosphatemia in RYGB patients treated with intravenous iron sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06350942 id: 1451_01/BVNTW-VNCSKTE briefTitle: One Trocar-assisted Retroperitoneoscopic Ureteroureterostomy for Ureteral Duplication overallStatus: COMPLETED date: 2016-09 date: 2020-12 date: 2024-02 date: 2024-04-08 date: 2024-04-08 name: National Children's Hospital, Vietnam class: OTHER name: Vinmec Research Institute of Stem Cell and Gene Technology briefSummary: Ureteral duplication, a common anomaly affecting about 0.8% of the population, presents challenges in pediatric urology due to its diverse clinical presentations and anatomical complexity. Traditional treatments like upper pole moiety (UPM) heminephrectomy can lead to loss of renal function in the remaining lower pole moiety (LPM). Ureteroureterostomy (UU) is a safer alternative, increasingly preferred regardless of renal function or reflux presence. Minimally invasive techniques like laparoscopic and robotic procedures show promise, but robotic-assisted UU is costly, while laparoscopic UU has technical challenges. A novel approach is proposed: single-trocar retroperitoneoscopic-assisted UU, combining laparoscopic visualization advantages with simplified extracorporeal suturing, offering a promising solution for managing complete ureteral duplication. The present study was designed to describe the operative technique and outcome of OTAU in 40 cases of complete ureteral duplication in children. conditions: Ureteral Duplication studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 40 type: ACTUAL name: one trocar-assisted retroperitoneoscopic ureteroureterostomy (OTAU) measure: Mean operating time measure: Intraoperative complications measure: Conversion to open measure: Early postoperative complications measure: Median length of hospital stays measure: Mean UPM renal pelvis' APD measure: Mean SFU of UPM renal pelvis measure: Mean UPM ureter's diameter measure: Mean UPM DRF measure: Mean DRF of operated side sex: ALL minimumAge: 1 Month maximumAge: 10 Years stdAges: CHILD facility: The National Hospital of Pediatrics city: Hanoi country: Vietnam lat: 21.0245 lon: 105.84117 facility: Vinmec Research Institute of Stem Cell and Gene Technology city: Hanoi country: Vietnam lat: 21.0245 lon: 105.84117 hasResults: False
nctId: NCT06350929 id: RC31/24/0017 briefTitle: Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients acronym: NORAFLOW overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2025-05 date: 2024-04-08 date: 2024-04-08 name: University Hospital, Toulouse class: OTHER briefSummary: Arterial hypotension is a frequent complication of general anesthesia and a significant contributor to postoperative complications. It is a critical marker for the development of acute renal failure and postoperative myocardial infarction. Chronic heart failure (CHF) patients are increasingly encountered in the operating room, and their perioperative morbidity and mortality are substantial, with specific management lacking precise recommendations.
The main objective is to assess the impact of a diluted norepinephrine bolus on cardiac output in chronic heart failure patients experiencing arterial hypotension after anesthesia induction. conditions: Hypotension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Cardiac output monitoring by the Starling™ SV Sebac® measure: Evaluation of the impact of a bolus of diluted norepinephrine on cardiac output in chronic heart failure patients presenting with arterial hypotension after anesthetic induction. measure: Evaluation of the role of preload dependence before anesthetic induction in the variation of cardiac output after a norepinephrine bolus. measure: Evaluation of the impact of the norepinephrine bolus on blood pressure correction. measure: Evaluation of the impact of the norepinephrine bolus on heart rate. measure: Evaluation of the safety of use of norepinephrine in chronic heart failure patients during hospitalization. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Toulouse Rangueil city: Toulouse zip: 31400 country: France name: François LABASTE, Dr role: CONTACT phone: 0561322822 phoneExt: +33 email: labaste.f@chu-toulouse.fr lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06350916 id: IRB00082594 id: LCI-GI-CRC-SEAMLESS-2020 type: OTHER domain: Atrium Health briefTitle: Application to Improve Patient Engagement and Decrease Postoperative Opioid Consumption in Patients for Colorectal Surgery overallStatus: COMPLETED date: 2021-01-28 date: 2021-07-30 date: 2021-10-01 date: 2024-04-08 date: 2024-04-08 name: Wake Forest University Health Sciences class: OTHER name: Atrium Health Levine Cancer Institute briefSummary: The purpose of this study is to evaluate whether patient-centered educational material delivered before and immediately after surgery can help improve outcomes for patients undergoing colorectal surgery. conditions: Colorectal Surgery studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 75 type: ACTUAL name: SeamlessMD® Mobile Application measure: Perioperative ERAS metric completion rate measure: Postoperative hospital length of stay measure: Postoperative complications measure: 30-day readmission measure: Postoperative Opioid Consumption sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Levine Cancer Institute city: Charlotte state: North Carolina zip: 28204 country: United States lat: 35.22709 lon: -80.84313 hasResults: False
nctId: NCT06350903 id: ICM 2024-3356 briefTitle: Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging acronym: SWEET-HEART overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-06 date: 2025-06 date: 2024-04-08 date: 2024-04-09 name: Matthieu Pelletier-Galarneau, MD MSc class: OTHER briefSummary: The overall objective of this study is to assess if the empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies. conditions: Myocardial Suppression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: DIAGNOSTIC masking: NONE count: 36 type: ESTIMATED name: Fast + High-fat low-carbohydrate diet name: Fast + Empagliflozin measure: Levels of serum Beta-hydroxybutyrate (BHB) mmol/L measure: Proportions of serum Beta-hydroxybutyrate (BHB) >0.5 mmol/L measure: Proportions of glycemia levels (mmol/L) <3.5 mmol/L measure: Acceptability and tolerance of each protocol, as reported by patients by a dedicated survey. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06350877 id: PA RCT briefTitle: 1:1 and Group-based Exercise Intervention for Post-secondary Student Mental Health and Well-being overallStatus: RECRUITING date: 2024-01-08 date: 2025-01 date: 2025-01 date: 2024-04-08 date: 2024-04-08 name: University of Toronto class: OTHER briefSummary: Post-secondary students report alarming rates of feeling overwhelmed, hopeless, anxious, and depressed. To better support student mental health, there is a well-documented need to improve the range and quality of mental health services available to students. Focussing on formalized treatment approaches and strategies supporting well-being in the campus community more generally are needed. Physical activity is an alternative therapeutic approach that could be implemented as an evidence-based lifestyle intervention for supporting mental health and well-being on post-secondary campuses.
Despite the growing evidence supporting physical activity for student mental health, there are significant knowledge gaps in the literature. First, there is a paucity of research exploring the effects of different delivery styles (i.e., one-on-one (1:1) vs. group) on primary (i.e., mental health symptomology including anxiety symptoms, depression symptoms, psychological distress) and secondary (i.e., social support, social connectedness) outcomes. Secondly, the maintenance effects of a physical activity program on mental health or sustained physical activity behaviour change are largely unknown. Lastly, limited research has explored contextual implementation factors (e.g., intervention reach, adherence, and program satisfaction) that may influence the sustainability and scale-up of physical activity programs for student mental health. Examining contextual implementation factors is critical for optimizing physical activity intervention delivery and for facilitating wider dissemination of research findings into practice. The goal of this 3-arm parallel randomized controlled trial is to test the effectiveness of 1:1 physical activity intervention and group-based physical activity intervention compared to a wait-list control group in supporting post-secondary student mental health. The main questions include: